checkpoint
therapeutics
participate
three
september
virtual
investor
conferences
new
york
globe
newswire
checkpoint
therapeutics
checkpoint
nasdaq
ckpt
immunotherapy
targeted
oncology
company
today
announced
james
oliviero
president
chief
executive
officer
participate
three
virtual
investor
conferences
september
details
events
follows
wainwright
nd
annual
global
investment
conference
presentation
monday
september
edt
annual
global
investment
conference
presentation
monday
september
edt
cantor
virtual
global
healthcare
conference
presentation
wednesday
september
edt
lake
street
capital
markets
annual
best
ideas
growth
conference
virtual
meetings
thursday
september
webcasts
presentations
available
events
page
located
within
investors
section
checkpoint
website
https
approximately
days
following
presentation
checkpoint
therapeutics
checkpoint
therapeutics
checkpoint
immunotherapy
targeted
oncology
company
focused
acquisition
development
commercialization
novel
treatments
patients
solid
tumor
cancers
checkpoint
evaluating
lead
antibody
product
candidate
cosibelimab
potential
antibody
licensed
cancer
institute
ongoing
global
multicohort
phase
clinical
trial
checkpoint
patients
selected
recurrent
metastatic
cancers
including
ongoing
cohorts
locally
advanced
metastatic
cutaneous
squamous
cell
carcinoma
intended
support
one
applications
marketing
approval
addition
checkpoint
evaluating
lead
targeted
agent
epidermal
growth
factor
receptor
egfr
inhibitor
potential
new
treatment
patients
egfr
cell
lung
cancer
checkpoint
headquartered
new
york
city
founded
fortress
biotech
information
visit
statements
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
statements
include
limited
statements
relating
plans
submit
one
biologics
license
applications
seek
approvals
cosibelimab
statements
regarding
potential
differentiation
cosibelimab
including
potentially
favorable
safety
profile
compared
currently
available
therapies
statements
relating
functional
fc
domain
cosibelimab
translating
potential
enhanced
efficacy
statements
relating
timing
completion
enrollment
full
results
statements
relating
long
believe
cash
fund
operations
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
value
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
regulatory
authorities
accept
application
approval
cosibelimab
based
data
ongoing
phase
study
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
risks
relating
timing
starting
completing
clinical
trials
uncertainties
relating
preclinical
clinical
testing
dependence
suppliers
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
securities
exchange
commission
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
required
law
company
contacts
jaclyn
jaffe
william
begien
checkpoint
therapeutics
ir
investor
relations
contact
ashley
robinson
managing
director
lifesci
advisors
llc
arr
media
relations
contact
tony
plohoros
degrees
tplohoros
